REGENXBIO (RGNX) Fundamentals 2026 — Revenue Analysis | SniperIQ
REGENXBIO (RGNX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $528M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is REGENXBIO's market cap?
REGENXBIO (RGNX) has a market capitalization of approximately $528M, trading at
What is REGENXBIO's P/E ratio?
REGENXBIO's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 25.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is REGENXBIO?
REGENXBIO runs a net profit margin of -330.2%, a gross margin of -0.1%, and an operating margin of -292.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does REGENXBIO generate?
REGENXBIO reported revenue of
Does REGENXBIO pay a dividend?
REGENXBIO does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is REGENXBIO financially healthy?
REGENXBIO carries a debt-to-equity ratio of 3.37x and a current ratio of 2.62x, with a market beta of 0.90. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is REGENXBIO a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For REGENXBIO (RGNX) the key facts are: market cap $528M, revenue
Track REGENXBIO's full fundamentals live
Get REGENXBIO's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.